Medtronic plc Stock News

Economists say the recession is canceled; the bond market is 98% sure it's still coming. The bond market is likely right, BUT history is very clear, the time to buy wonderful companies at wonderful pr

Because of their underappreciated value factor, most dividend stocks tend to be top performers over long holding periods. AT&T and Medtronic offer investors high yields and extremely attractive valuat

Medtronic (MDT) closed the most recent trading day at $70.56, moving +0.84% from the previous trading session.

Medtronic's diversification and excellent dividend make it a good pick for conservative investors. Alphabet's stock recently took a dive, but the company retains its leadership in multiple industries.

Medtronic (MDT) closed at $69.97 in the latest trading session, marking a +0.78% move from the prior day.

As I type this, equity investors can relate to the statement “nowhere to run, nowhere to hide.” The tech-heavy NASDAQ index is down over 4% in the five days ending Oct. 26.

Medtronic is a global medical technology company specializing in various medical devices. The company's revenues are well distributed among different segments, with cardiovascular being the largest se

The current bear market presents excellent buying opportunities for high-quality dividend stocks. Many stocks, especially dividend stocks, have dropped due to fear and uncertainty, creating attractive

Medtronic and PayPal are two stocks whose valuations have nosedived since 2021. Medtronic's exposure to China is a concern, but its earnings and cash flow remain resilient.

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength

With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 5

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

UBS' Jason Draho and Hightower's Michael Farr, join 'Power Lunch' to discuss how investors should position in a volatile bond market.

Investors are worried that the stock market's first-half performance in 2023 is reversing. It's unclear what part of the business cycle we are currently in.

Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.